GlassScriptPhysician profile
Jeffrey N Gordon
NPI 1124068044
$17,012.00
in general payments reported to CMS, 2019-2025
40 companies · $2,535 in 2025
The $2,535 reported for 2025 was more than what 84% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,621 · 2020: $1,856 · 2021: $508 · 2022: $4,973 · 2023: $2,147 · 2024: $2,371 · 2025: $2,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,718 · Consulting Fee: $225 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,718.40 |
| Consulting Fee | $225.00 |
| Education | $109.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $4,594.43 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $2,498.62 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $1,390.80 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Boston Scientific Corporation | $1,188.34 | 2019-2024 | Rezum Generator |
| Astellas Pharma US INC | $1,097.72 | 2019-2025 | Xtandi, Myrbetriq |
| Procept Biorobotics Corporation | $995.73 | 2022-2025 | Aquabeam System |
| Pfizer INC. | $694.97 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $491.37 | 2023-2025 | Orgovyx, Gemtesa |
| Progenics Pharmaceuticals, INC. | $442.15 | 2023-2025 | Pylarify |
| Ferring Pharmaceuticals INC. | $436.51 | 2019-2025 | Adstiladrin |
| Myriad Genetic Laboratories, INC. | $394.89 | 2020-2024 | Prolaris |
| Merck Sharp & Dohme LLC | $269.00 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $236.25 | 2023-2025 | |
| Teleflex LLC | $233.19 | 2021-2025 | Urolift, Barrigel |
| Medtronic, INC. | $195.46 | 2023-2025 | Interstim |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $182.73 | 2019-2024 | Yonsa, Odomzo |
| Biosense Webster, INC. | $167.92 | 2024 | Carto 3 |
| Neotract INC. | $164.99 | 2019-2020 | |
| Abbvie INC. | $153.30 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $144.62 | 2023 | Erleada |
| Tolmar, INC. | $137.66 | 2023-2025 | Eligard, Jatenzo |
| Myovant Sciences INC. | $136.32 | 2021-2022 | |
| Telix Pharmaceuticals | $133.01 | 2023-2025 | Illuccix |
| Astrazeneca Pharmaceuticals LP | $119.44 | 2024-2025 | Lynparza |
| Urogen Pharma, INC. | $112.90 | 2022-2025 | Jelmyto |
| Verity Pharmaceuticals INC. | $68.57 | 2022-2025 | Trelstar, Tlando |
| Palette Life Sciences, INC. | $65.97 | 2022-2023 | |
| Olympus America INC. | $38.21 | 2025 | Itind System |
| Astellas Pharma Global Development | $33.79 | 2024 | Xtandi |
| Dentsply Ih Ab | $28.24 | 2023 | Lofric |
| Blue Earth Diagnostics | $26.34 | 2024 | |
| Tolmar Pharmaceuticals, INC. | $24.84 | 2022 | |
| Calyxo, INC. | $24.49 | 2024 | Cvac Aspiration System |
| Urovant Sciences INC | $24.19 | 2022 | |
| Avadel Specialty Pharmaceuticals, LLC | $19.35 | 2019 | |
| Allergan, INC. | $14.31 | 2020 | |
| Axonics, INC. | $14.24 | 2022 | |
| Immunitybio, INC. | $13.81 | 2024 | |
| Mission Pharmacal Company | $3.33 | 2023 | Uribel |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.